Pepine C J, Gelman J S
Br J Clin Pharmacol. 1985;20 Suppl 1(Suppl 1):187S-194S. doi: 10.1111/j.1365-2125.1985.tb05163.x.
Anti-ischaemic effects and safety of nicardipine were assessed in 14 patients with vasospastic angina using a placebo comparison, cross-over design study for 8-13 weeks. The average daily dose of nicardipine for optimal angina prevention was 84 mg (range 40-160 mg). Nicardipine administration, as compared with placebo, significantly reduced anginal frequency and nitroglycerin consumption during the single- and double-blind phases of the study. Nicardipine appears to be effective in the prevention of vasospastic angina and not to cause major adverse effects.
采用安慰剂对照、交叉设计研究,对14例血管痉挛性心绞痛患者进行了为期8至13周的尼卡地平抗缺血作用及安全性评估。预防心绞痛的尼卡地平最佳日平均剂量为84毫克(范围40 - 160毫克)。与安慰剂相比,在研究的单盲和双盲阶段,尼卡地平治疗可显著降低心绞痛发作频率及硝酸甘油用量。尼卡地平似乎对预防血管痉挛性心绞痛有效且不会引起严重不良反应。